- Tempest Therapeutics Inc To Discuss Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Call TranscriptOct 11, 2023
- Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Tempest Therapeutics Inc Annual Shareholders Meeting TranscriptJun 15, 2023
- Tempest Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Tempest Therapeutics Inc To Discuss Phase 1b/2 Combination Study of TPST-1120 in First-Line HCC Data Call TranscriptApr 28, 2023
- Tempest Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Tempest Therapeutics Inc Annual Shareholders Meeting TranscriptJun 17, 2022
- Tempest Therapeutics Inc At ASCO Call TranscriptJun 05, 2022
- Millendo Therapeutics Inc And Tempest Therapeutics Inc Merger - M&A Call TranscriptMar 29, 2021
Tempest Therapeutics Inc To Discuss Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Call Transcript
Good morning, and thank you all for joining the Tempest Therapeutics conference call. At this time, all participants are in listen-only mode. As a reminder, today's conference call is being recorded. Following management's remarks, we will hold a question-and-answer session, and at that time, the lines will be open.
I would now like to turn the call over to Aljanae Reynolds. Please go ahead.
Thank you, operator, and good morning, everyone. Thank you for joining our call to discuss the new positive data from the global randomized trial of TPST-1120 in first-line liver cancer. For your reference, a press release covering the news is available on the company's website at tempesttx.com.
Joining me on the call today are Steve Brady, President and Chief Executive Officer; and Dr. Sam Whiting, Chief Medical Officer and Head of Research and Development.
Turning to slide 2. During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)